# NSD3

Source: https://onco.cc/targets/nsd3/  
OnCo record `nsd3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

NSD3 (Histone-lysine N-methyltransferase NSD3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Breast cancer, Skin cancer, Colorectal cancer and 1 more.

## Summary

Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression.

Open Targets scores its association with cancer at 0.65 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.19, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Lung Squamous Cell Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: nuclear receptor binding SET domain protein 3; Histone-lysine N-methyltransferase NSD3; FLJ20353; WHISTLE; KMT3F; WHSC1L1
- Tags: cancer-genes-wave
- Symbol: NSD3
- Class: tumor-suppressor
- Biology: Histone methyltransferase. Preferentially dimethylates 'Lys-4' and 'Lys-27' of histone H3 forming H3K4me2 and H3K27me2. H3 'Lys-4' methylation represents a specific tag for epigenetic transcriptional activation, while 'Lys-27' is a mark for transcriptional repression. Location: Nucleus; Chromosome (UniProt). Locus 8p11.23 (HGNC).
- Where found: Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254); Skin cancer: Open Targets association 0.52 with skin cancer (MONDO_0002898); Colorectal cancer: Open Targets association 0.51 with colorectal cancer (MONDO_0005575); Non-small-cell lung cancer: IntOGen driver in 1 cohort (LUSC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:12767: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12767
- UniProt Q9BZ95: https://www.uniprot.org/uniprotkb/Q9BZ95/entry
- NCBI Gene 54904: https://www.ncbi.nlm.nih.gov/gene/54904
- Ensembl ENSG00000147548: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000147548

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)

---
JSON: https://onco.cc/api/v1/entities/nsd3.json